|
|
|
|
Compared with placebo treatment, pergolide treatment was associated with significantly lower TGTSS scores (42.0 +/- 20.4 versus 23.5 +/- 18.7; F=12.0, df=1, 17, p=0.0011). No patient had a serious adverse event and pergolide was well tolera ted. In this randomized, placebo-controlled, crossover trial, pergolide appeared to be a safe and efficacious treatment for Tourette's syndrome in children. |
|